DrugMapper


Trade Names:	HYDROCODONE BITARTRATE HYSINGLA ER VANTRELA ER ZOHYDRO ER
Synonyms:	CEP-33237 Dicodid Dihydrocodeinone bitartrate Hycodan Hydrocodone bitartrate Hydrocodone bitartrate cii Hydrocodone bitartrate hemipentahydrate Hydrocodone tartrate Hysingla Hysingla er Mercodinone Vantrela Vantrela er Zohydro Zohydro er
Status:	Approved (1943)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	NO70W886KK
Parent Compound:	HYDROCODONE


InChI Key	OJHZNMVJJKMFGX-RNWHKREASA-N
Smile	COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O=C(O)C(O)C(O)C(=O)O
InChI	InChI=1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;/m0./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H31NO11
Molecular Weight	485.49
AlogP	1.93
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	1.0
Polar Surface Area	38.77
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	22.0

Action	Mechanism of Action	Reference
AGONIST	Opioid receptors; mu/kappa/delta agonist	PubMed FDA

Mesh Heading	Maximum Phase	Mesh ID	Reference
Low Back Pain	3	D017116	ClinicalTrials
Neuralgia	3	D009437	ClinicalTrials
Chronic Pain	3	D059350	ClinicalTrials
Rotator Cuff Injuries	2	D000070636	ClinicalTrials
Wounds and Injuries	2	D014947	ClinicalTrials
Osteoarthritis	2	D010003	ClinicalTrials
Substance-Related Disorders	1	D019966	ClinicalTrials
Kidney Diseases	1	D007674	ClinicalTrials
Liver Diseases	1	D008107	ClinicalTrials

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	26.28
Psychiatric disorders	13.46
Nervous system disorders	13.35
Gastrointestinal disorders	12.56
Injury, poisoning and procedural complications	8.99
Cardiac disorders	4.17
Skin and subcutaneous tissue disorders	3.59
Respiratory, thoracic and mediastinal disorders	3.34
Vascular disorders	3.19
Musculoskeletal and connective tissue disorders	2.05

Resources	Reference
ChEMBL	CHEMBL3989677
FDA SRS	NO70W886KK
PubChem	23724881

HYDROCODONE BITARTRATE

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

Scaffolds

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70